oxybutynin has been researched along with Hyperhidrosis in 57 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Hyperhidrosis: Excessive sweating. In the localized type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Its chief cause is thought to be emotional. Generalized hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate efficacy of 20% oxybutynin hydrochloride lotion (20% OL) in reducing palmar sweat volume in patients with primary palmar hyperhidrosis (PPHH)." | 9.69 | A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study. ( Fujimoto, T; Hirayama, Y; Inakura, H; Okawa, K; Terahara, T; Yokozeki, H, 2023) |
| "Oxybutynin gel and nanoemulgel offer equal safety and similar efficacy in reducing the disease severity and increasing the quality of life of patients with palmar hyperhidrosis." | 9.69 | Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial. ( Ahramiyanpour, N; Alipour, S; Hosseini, SA; Rastaghi, F; Saki, N; Shakouri, N, 2023) |
| "The long-term safety and efficacy of 52-week application of oxybutynin hydrochloride 20% lotion (20% OL) for the treatment of primary palmar hyperhidrosis (PPHH) in Japanese patients aged ≥12 years were evaluated in an open-label extension (OLE) of a 4-week, randomized, double-blind (DB) study." | 9.69 | Long-term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open-label extension study. ( Fujimoto, T; Hirayama, Y; Inakura, H; Okawa, K; Terahara, T; Yokozeki, H, 2023) |
| "Our study suggests that using oxybutynin as a treatment for hyperhidrosis is significant and needs to be highlighted for clinicians." | 9.41 | Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. ( Abdelwahab, OA; Amro, S; Badawy, MM; El-Samahy, M; Fayad, T; Mouffokes, A, 2023) |
| "Oral oxybutynin for treating hyperhidrosis is effective and safe." | 9.24 | Initial study of transdermal oxybutynin for treating hyperhidrosis. ( de Troya-Martín, M; Del Boz, J; García-Montero, P; Millán-Cayetano, JF; Nieto-Guindo, M; Toledo-Pastrana, T, 2017) |
| "To evaluate the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis." | 9.20 | Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. ( Abasq-Thomas, C; Brenaut, E; Chassain-Le Lay, M; Dupré-Goetghebeur, D; Gouedard, C; Greco, M; Jouan, N; Le Gal, G; Le Ru, Y; Menard-Andivot, N; Misery, L; Penven, K; Pillette-Delarue, M; Roguedas-Contios, AM; Sassolas, B; Schollhammer, M; Zagnoli, A, 2015) |
| "Oxybutynin was effective in the treatment of persistent plantar hyperhidrosis, resulting in a better quality of life in women who had undergone thoracoscopic sympathectomy." | 9.19 | Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. ( Costa, Ada S; Filho Aurelio Marchetti, M; Filho Castelo, A; Leão, LE; Perfeito, JA; Rymkiewicz, E; Succi, JE, 2014) |
| "Among patients with good initial responses to oxybutynin, more than 90 % experienced moderate or great improvement in their palmar sweating, as well as in their hyperhidrosis in other sites, after 6 months." | 9.19 | Long-term results of oxybutynin treatment for palmar hyperhidrosis. ( de Campos, JR; de Paula, RP; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "This study evaluated the effectiveness and patient satisfaction of oral oxybutynin at low doses (5 mg twice daily) compared with placebo for treating palmar hyperhidrosis." | 9.16 | A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. ( de Campos, JR; Kauffman, P; Puech-Leão, P; Wolosker, N, 2012) |
| "The use of oxybutynin is an alternative as the first step in the treatment of palmar hyperhidrosis, given that it presents good results and improves QOL." | 9.15 | An alternative to treat palmar hyperhidrosis: use of oxybutynin. ( de Campos, JR; Jatene, FB; Kauffman, P; Neves, S; Puech-Leão, P; Wolosker, N; Yazbek, G, 2011) |
| "This study included a large number of patients followed for a long period and demonstrated the good effectiveness of treatment with oxybutynin for hyperhidrosis in the main sites of sweating." | 7.96 | Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases. ( da Silva, MFA; de Campos, JRM; Faustino, CB; Kauffman, P; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2020) |
| "Oxybutynin chloride and botulinum toxin type A (BTX-A) have demonstrated to be effective treatments for primary palmar hyperhidrosis (PPH); however, both of them are not completely free from local and/or generalized side effects." | 7.96 | Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study. ( Bobyr, I; Campanati, A; Consales, V; Diotallevi, F; Gregoriou, S; Kontochristopoulos, G; Martina, E; Offidani, A; Platsidaki, E; Rizzetto, G, 2020) |
| "Oral oxybutynin (OOx) is an effective and safe treatment for the treatment of hyperhidrosis (HH)." | 7.96 | Tolerance of oral oxybutynin in the treatment of hyperhidrosis. ( de Troya Martin, M; Del Boz Gonzalez, J; Millán-Cayetano, JF; Rodríguez Barón, D, 2020) |
| "Oral anticholinergics such as oxybutynin (OOx) and glycopyrrolate (OGly) are frequently used in the management of hyperhidrosis." | 7.96 | Survival study of treatment adherence by patients given oral glycopyrrolate for hyperhidrosis following treatment failure with oral oxybutynin. ( Del Boz, J; García-Souto, F; Polo-Padillo, J; Rivas-Ruiz, F, 2020) |
| "There was a significant improvement in quality of life and a reduction in sweating and malodor after six weeks of treatment with topical agents and oxybutynin in patients with both hyperhidrosis and osmidrosis." | 7.88 | Combination of topical agents and oxybutynin as a therapeutic modality for patients with both osmidrosis and hyperhidrosis. ( Campos, JRM; Fukuda, JM; Kauffman, P; Mendes, CA; Pinheiro, LL; Teivelis, MP; Varella, AYM; Wolosker, N, 2018) |
| "Most studies of oral oxybutynin (OOx) for the treatment of hyperhidrosis (HH) have assumed a stable treatment protocol, without taking into account adverse effects (AE) or seasonal variations in temperature." | 7.88 | Adjusting oral oxybutynin medication for hyperhidrosis to reflect seasonal temperature variations. ( de Troya-Martín, M; Del Boz, J; García-Harana, C; García-Montero, P; Millán-Cayetano, JF; Rivas-Ruiz, F, 2018) |
| "Oxybutynin 3% gel reduced hyperhidrosis severity and improved health-related quality of life in this small pilot study." | 7.88 | Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. ( Abbott, J; Bruckner, AL; Gralla, J; Nguyen, NV, 2018) |
| "Oral oxybutynin may be an effective and safe option for the long-term treatment of hyperhidrosis." | 7.85 | Oral oxybutynin for the treatment of hyperhidrosis: outcomes after one-year follow-up. ( Blázquez-Sánchez, N; de Troya-Martín, M; Del Boz, J; Hernández Ibáñez, C; Millán-Cayetano, JF; Rivas-Ruiz, F, 2017) |
| "This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating." | 7.83 | Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis. ( Bergón-Sendín, M; Pulido-Pérez, A; Sáez-Martín, LC; Suárez-Fernández, R, 2016) |
| "Oral anticholinergic drugs, such as oxybutynin, are often used in the treatment of hyperhidrosis, but few studies have focused on dosing strategies for children." | 7.83 | Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers. ( Blázquez-Sánchez, N; de Troya, M; Del Boz, J; Millán-Cayetano, JF, 2016) |
| "From September 2007 to September 2013, 85 consecutive patients were enrolled in our institutional protocol for the "pharmacological-first" treatment of primary plantar hyperhidrosis with oxybutynin." | 7.81 | Long-term results of the use of oxybutynin for the treatment of plantar hyperhidrosis. ( de Campos, JR; de Paula, RP; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2015) |
| " Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects." | 7.80 | Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin. ( Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "Improvements in hyperhidrosis after oxybutynin treatment were similar in both groups, suggesting that QOL before treatment is not a predictive factor for clinical outcomes, contrasting with surgical results that disclose significantly better results in patients with initially poorer QOL analysis." | 7.80 | Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis. ( Campbell, TP; de Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "From January 2007 to December 2010, 35 consecutive patients with plantar hyperhidrosis were treated with oxybutynin." | 7.79 | Use of oxybutynin for treating plantar hyperhidrosis. ( de Campos, JR; Kauffman, P; Neves, S; Puech-Leao, P; Wolosker, N; Yazbek, G, 2013) |
| "Oxybutynin is being increasingly being prescribed in the treatment of hyperhidrosis but currently, there is no precise dosage for this treatment." | 7.78 | [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis]. ( Aubin, F; Elkhyat, A; Humbert, RP; Messikh, R; Try, C, 2012) |
| "To evaluate the effectiveness and patient satisfaction with the use of oxybutynin for treating axillary hyperhidrosis in a large series of patients." | 7.77 | The use of oxybutynin for treating axillary hyperhidrosis. ( BiscegliJatene, F; de Campos, JR; Kauffman, P; Munia, MA; Neves, S; Puech-Leão, P; Wolosker, N, 2011) |
| "All patients treated with oxybutynin between February 2008 and October 2010 for troublesome generalized hyperhidrosis were recruited after ruling out underlying disease." | 7.77 | [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis]. ( Bara, C; Célérier, P; Fenot, M; Maillard, H, 2011) |
| "Hyperhidrosis may affect nearly 3% of the population, and thoracic/lumbar sympathectomy has been highly effective." | 6.79 | Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin. ( Kauffman, P; Krutman, M; Milanez de Campos, JR; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "Hyperhidrosis is a disorder of excessive sweating severely impacting on patient's quality of life (Qol)." | 6.72 | Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature. ( Argenziano, G; Babino, G; Briatico, G; Caccavale, S; D'Ambra, I; Fulgione, E; Giorgio, CM; Longo, C; Pampena, R, 2021) |
| "To evaluate efficacy of 20% oxybutynin hydrochloride lotion (20% OL) in reducing palmar sweat volume in patients with primary palmar hyperhidrosis (PPHH)." | 5.69 | A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study. ( Fujimoto, T; Hirayama, Y; Inakura, H; Okawa, K; Terahara, T; Yokozeki, H, 2023) |
| "Oxybutynin gel and nanoemulgel offer equal safety and similar efficacy in reducing the disease severity and increasing the quality of life of patients with palmar hyperhidrosis." | 5.69 | Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial. ( Ahramiyanpour, N; Alipour, S; Hosseini, SA; Rastaghi, F; Saki, N; Shakouri, N, 2023) |
| "The long-term safety and efficacy of 52-week application of oxybutynin hydrochloride 20% lotion (20% OL) for the treatment of primary palmar hyperhidrosis (PPHH) in Japanese patients aged ≥12 years were evaluated in an open-label extension (OLE) of a 4-week, randomized, double-blind (DB) study." | 5.69 | Long-term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open-label extension study. ( Fujimoto, T; Hirayama, Y; Inakura, H; Okawa, K; Terahara, T; Yokozeki, H, 2023) |
| "Hyperhidrosis is a condition of excessive sweating beyond physiological parameters that can seriously impair quality of life." | 5.56 | Oxybutynin in primary hyperhidrosis: A long-term real-life study. ( Almeida, ART; Ferrari, F; Restrepo, MVS; Rocha, VB, 2020) |
| " It also demonstrates a rare drug adverse effect with successful treatment." | 5.43 | Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment. ( Fischer, R; Liu, D; Prouty, ME, 2016) |
| "Our study suggests that using oxybutynin as a treatment for hyperhidrosis is significant and needs to be highlighted for clinicians." | 5.41 | Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. ( Abdelwahab, OA; Amro, S; Badawy, MM; El-Samahy, M; Fayad, T; Mouffokes, A, 2023) |
| "Oxybutynin was a well-tolerated, effective, and safe method for treating postmenopausal sweating." | 5.36 | Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients. ( Kil, HK; Kim, WO; Yoo, JH; Yoon, KB, 2010) |
| "Oral oxybutynin for treating hyperhidrosis is effective and safe." | 5.24 | Initial study of transdermal oxybutynin for treating hyperhidrosis. ( de Troya-Martín, M; Del Boz, J; García-Montero, P; Millán-Cayetano, JF; Nieto-Guindo, M; Toledo-Pastrana, T, 2017) |
| "To evaluate the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis." | 5.20 | Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. ( Abasq-Thomas, C; Brenaut, E; Chassain-Le Lay, M; Dupré-Goetghebeur, D; Gouedard, C; Greco, M; Jouan, N; Le Gal, G; Le Ru, Y; Menard-Andivot, N; Misery, L; Penven, K; Pillette-Delarue, M; Roguedas-Contios, AM; Sassolas, B; Schollhammer, M; Zagnoli, A, 2015) |
| "Oxybutynin was effective in the treatment of persistent plantar hyperhidrosis, resulting in a better quality of life in women who had undergone thoracoscopic sympathectomy." | 5.19 | Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. ( Costa, Ada S; Filho Aurelio Marchetti, M; Filho Castelo, A; Leão, LE; Perfeito, JA; Rymkiewicz, E; Succi, JE, 2014) |
| "Among patients with good initial responses to oxybutynin, more than 90 % experienced moderate or great improvement in their palmar sweating, as well as in their hyperhidrosis in other sites, after 6 months." | 5.19 | Long-term results of oxybutynin treatment for palmar hyperhidrosis. ( de Campos, JR; de Paula, RP; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "This study evaluated the effectiveness and patient satisfaction of oral oxybutynin at low doses (5 mg twice daily) compared with placebo for treating palmar hyperhidrosis." | 5.16 | A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. ( de Campos, JR; Kauffman, P; Puech-Leão, P; Wolosker, N, 2012) |
| "The use of oxybutynin is an alternative as the first step in the treatment of palmar hyperhidrosis, given that it presents good results and improves QOL." | 5.15 | An alternative to treat palmar hyperhidrosis: use of oxybutynin. ( de Campos, JR; Jatene, FB; Kauffman, P; Neves, S; Puech-Leão, P; Wolosker, N; Yazbek, G, 2011) |
| "Oxybutynin chloride and botulinum toxin type A (BTX-A) have demonstrated to be effective treatments for primary palmar hyperhidrosis (PPH); however, both of them are not completely free from local and/or generalized side effects." | 3.96 | Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study. ( Bobyr, I; Campanati, A; Consales, V; Diotallevi, F; Gregoriou, S; Kontochristopoulos, G; Martina, E; Offidani, A; Platsidaki, E; Rizzetto, G, 2020) |
| "Oral anticholinergics such as oxybutynin (OOx) and glycopyrrolate (OGly) are frequently used in the management of hyperhidrosis." | 3.96 | Survival study of treatment adherence by patients given oral glycopyrrolate for hyperhidrosis following treatment failure with oral oxybutynin. ( Del Boz, J; García-Souto, F; Polo-Padillo, J; Rivas-Ruiz, F, 2020) |
| "Oral oxybutynin (OOx) is an effective and safe treatment for the treatment of hyperhidrosis (HH)." | 3.96 | Tolerance of oral oxybutynin in the treatment of hyperhidrosis. ( de Troya Martin, M; Del Boz Gonzalez, J; Millán-Cayetano, JF; Rodríguez Barón, D, 2020) |
| "This study included a large number of patients followed for a long period and demonstrated the good effectiveness of treatment with oxybutynin for hyperhidrosis in the main sites of sweating." | 3.96 | Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases. ( da Silva, MFA; de Campos, JRM; Faustino, CB; Kauffman, P; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2020) |
| "This study was conducted to identify the variables associated with adherence to treatment by hyperhidrosis patients treated with oral oxybutynin." | 3.88 | Survival study of treatment adherence by patients given oral oxibutynin for hyperhidrosis. ( de Troya-Martín, M; Del Boz, J; García-Harana, C; García-Montero, P; Millán-Cayetano, JF; Rivas Ruiz, F, 2018) |
| "Most studies of oral oxybutynin (OOx) for the treatment of hyperhidrosis (HH) have assumed a stable treatment protocol, without taking into account adverse effects (AE) or seasonal variations in temperature." | 3.88 | Adjusting oral oxybutynin medication for hyperhidrosis to reflect seasonal temperature variations. ( de Troya-Martín, M; Del Boz, J; García-Harana, C; García-Montero, P; Millán-Cayetano, JF; Rivas-Ruiz, F, 2018) |
| "There was a significant improvement in quality of life and a reduction in sweating and malodor after six weeks of treatment with topical agents and oxybutynin in patients with both hyperhidrosis and osmidrosis." | 3.88 | Combination of topical agents and oxybutynin as a therapeutic modality for patients with both osmidrosis and hyperhidrosis. ( Campos, JRM; Fukuda, JM; Kauffman, P; Mendes, CA; Pinheiro, LL; Teivelis, MP; Varella, AYM; Wolosker, N, 2018) |
| "Oxybutynin 3% gel reduced hyperhidrosis severity and improved health-related quality of life in this small pilot study." | 3.88 | Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. ( Abbott, J; Bruckner, AL; Gralla, J; Nguyen, NV, 2018) |
| "VATS showed good results in patients with palmar or axillary hyperhidrosis regarding surgical response and improvement on quality of life even when the previous oxybutynin chloride treatment failed." | 3.85 | Videothoracoscopic Sympathectomy Results after Oxybutynin Chloride Treatment Failure. ( de Campos, JRM; Kauffman, P; Lembrança, L; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2017) |
| "Oral oxybutynin may be an effective and safe option for the long-term treatment of hyperhidrosis." | 3.85 | Oral oxybutynin for the treatment of hyperhidrosis: outcomes after one-year follow-up. ( Blázquez-Sánchez, N; de Troya-Martín, M; Del Boz, J; Hernández Ibáñez, C; Millán-Cayetano, JF; Rivas-Ruiz, F, 2017) |
| "This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating." | 3.83 | Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis. ( Bergón-Sendín, M; Pulido-Pérez, A; Sáez-Martín, LC; Suárez-Fernández, R, 2016) |
| "Oral anticholinergic drugs, such as oxybutynin, are often used in the treatment of hyperhidrosis, but few studies have focused on dosing strategies for children." | 3.83 | Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers. ( Blázquez-Sánchez, N; de Troya, M; Del Boz, J; Millán-Cayetano, JF, 2016) |
| "From September 2007 to September 2013, 85 consecutive patients were enrolled in our institutional protocol for the "pharmacological-first" treatment of primary plantar hyperhidrosis with oxybutynin." | 3.81 | Long-term results of the use of oxybutynin for the treatment of plantar hyperhidrosis. ( de Campos, JR; de Paula, RP; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2015) |
| " Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects." | 3.80 | Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin. ( Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "Improvements in hyperhidrosis after oxybutynin treatment were similar in both groups, suggesting that QOL before treatment is not a predictive factor for clinical outcomes, contrasting with surgical results that disclose significantly better results in patients with initially poorer QOL analysis." | 3.80 | Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis. ( Campbell, TP; de Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "From January 2007 to December 2010, 35 consecutive patients with plantar hyperhidrosis were treated with oxybutynin." | 3.79 | Use of oxybutynin for treating plantar hyperhidrosis. ( de Campos, JR; Kauffman, P; Neves, S; Puech-Leao, P; Wolosker, N; Yazbek, G, 2013) |
| "Oxybutynin is being increasingly being prescribed in the treatment of hyperhidrosis but currently, there is no precise dosage for this treatment." | 3.78 | [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis]. ( Aubin, F; Elkhyat, A; Humbert, RP; Messikh, R; Try, C, 2012) |
| "All patients treated with oxybutynin between February 2008 and October 2010 for troublesome generalized hyperhidrosis were recruited after ruling out underlying disease." | 3.77 | [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis]. ( Bara, C; Célérier, P; Fenot, M; Maillard, H, 2011) |
| "To evaluate the effectiveness and patient satisfaction with the use of oxybutynin for treating axillary hyperhidrosis in a large series of patients." | 3.77 | The use of oxybutynin for treating axillary hyperhidrosis. ( BiscegliJatene, F; de Campos, JR; Kauffman, P; Munia, MA; Neves, S; Puech-Leão, P; Wolosker, N, 2011) |
| "Hyperhidrosis may affect nearly 3% of the population, and thoracic/lumbar sympathectomy has been highly effective." | 2.79 | Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin. ( Kauffman, P; Krutman, M; Milanez de Campos, JR; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "Hyperhidrosis is a disorder of excessive sweating severely impacting on patient's quality of life (Qol)." | 2.72 | Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature. ( Argenziano, G; Babino, G; Briatico, G; Caccavale, S; D'Ambra, I; Fulgione, E; Giorgio, CM; Longo, C; Pampena, R, 2021) |
| "Hyperhidrosis is a condition of excessive sweating beyond physiological parameters that can seriously impair quality of life." | 1.56 | Oxybutynin in primary hyperhidrosis: A long-term real-life study. ( Almeida, ART; Ferrari, F; Restrepo, MVS; Rocha, VB, 2020) |
| " It also demonstrates a rare drug adverse effect with successful treatment." | 1.43 | Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment. ( Fischer, R; Liu, D; Prouty, ME, 2016) |
| "Oxybutynin was a well-tolerated, effective, and safe method for treating postmenopausal sweating." | 1.36 | Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients. ( Kil, HK; Kim, WO; Yoo, JH; Yoon, KB, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.75) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 7 (12.28) | 29.6817 |
| 2010's | 36 (63.16) | 24.3611 |
| 2020's | 12 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| El-Samahy, M | 1 |
| Mouffokes, A | 1 |
| Badawy, MM | 1 |
| Amro, S | 1 |
| Fayad, T | 1 |
| Abdelwahab, OA | 1 |
| Fujimoto, T | 2 |
| Terahara, T | 2 |
| Okawa, K | 2 |
| Inakura, H | 2 |
| Hirayama, Y | 2 |
| Yokozeki, H | 2 |
| Saki, N | 1 |
| Shakouri, N | 1 |
| Rastaghi, F | 1 |
| Hosseini, SA | 1 |
| Alipour, S | 1 |
| Ahramiyanpour, N | 1 |
| Wolosker, N | 14 |
| Kauffman, P | 14 |
| de Campos, JRM | 2 |
| Faustino, CB | 1 |
| da Silva, MFA | 1 |
| Teivelis, MP | 10 |
| Puech-Leão, P | 13 |
| Campanati, A | 2 |
| Gregoriou, S | 2 |
| Consales, V | 1 |
| Rizzetto, G | 1 |
| Bobyr, I | 1 |
| Diotallevi, F | 1 |
| Martina, E | 1 |
| Kontochristopoulos, G | 2 |
| Platsidaki, E | 2 |
| Offidani, A | 1 |
| Del Boz Gonzalez, J | 1 |
| Rodríguez Barón, D | 1 |
| Millán-Cayetano, JF | 7 |
| de Troya Martin, M | 1 |
| Del Boz, J | 8 |
| García-Souto, F | 2 |
| Rivas-Ruiz, F | 4 |
| Polo-Padillo, J | 2 |
| Almeida, ART | 1 |
| Ferrari, F | 1 |
| Restrepo, MVS | 1 |
| Rocha, VB | 1 |
| Colmenero-Sendra, M | 1 |
| Briatico, G | 1 |
| Pampena, R | 1 |
| Fulgione, E | 1 |
| Babino, G | 1 |
| Giorgio, CM | 1 |
| D'Ambra, I | 1 |
| Caccavale, S | 1 |
| Longo, C | 1 |
| Argenziano, G | 1 |
| Markantoni, V | 1 |
| Agiasofitou, E | 1 |
| Kouris, A | 1 |
| Offidani, AM | 1 |
| Rigopoulos, D | 1 |
| Prouty, ME | 1 |
| Fischer, R | 1 |
| Liu, D | 1 |
| Lembrança, L | 1 |
| Jarrett, JB | 1 |
| Moss, D | 1 |
| Artzi, O | 1 |
| Loizides, C | 1 |
| Zur, E | 1 |
| Sprecher, E | 1 |
| García-Montero, P | 3 |
| García-Harana, C | 2 |
| Rivas Ruiz, F | 1 |
| de Troya-Martín, M | 5 |
| Nguyen, NV | 1 |
| Gralla, J | 1 |
| Abbott, J | 1 |
| Bruckner, AL | 1 |
| Varella, AYM | 1 |
| Fukuda, JM | 2 |
| Pinheiro, LL | 1 |
| Mendes, CA | 1 |
| Campos, JRM | 1 |
| de Campos, JR | 8 |
| Yazbek, G | 2 |
| Neves, S | 3 |
| Krutman, M | 6 |
| Campbell, TP | 1 |
| de Paula, RP | 3 |
| Costa, Ada S | 1 |
| Leão, LE | 1 |
| Succi, JE | 1 |
| Perfeito, JA | 1 |
| Filho Castelo, A | 1 |
| Rymkiewicz, E | 1 |
| Filho Aurelio Marchetti, M | 1 |
| Milanez de Campos, JR | 1 |
| Campos, JR | 2 |
| Baumgartner, F | 1 |
| Karlsson-Groth, A | 1 |
| Rystedt, A | 1 |
| Swartling, C | 1 |
| Nicholas, R | 1 |
| Quddus, A | 1 |
| Baker, DM | 1 |
| Schollhammer, M | 2 |
| Brenaut, E | 1 |
| Menard-Andivot, N | 1 |
| Pillette-Delarue, M | 1 |
| Zagnoli, A | 1 |
| Chassain-Le Lay, M | 1 |
| Sassolas, B | 1 |
| Jouan, N | 1 |
| Le Ru, Y | 1 |
| Abasq-Thomas, C | 1 |
| Greco, M | 1 |
| Penven, K | 1 |
| Roguedas-Contios, AM | 1 |
| Dupré-Goetghebeur, D | 1 |
| Gouedard, C | 1 |
| Misery, L | 2 |
| Le Gal, G | 1 |
| Vary, JC | 1 |
| Blázquez-Sánchez, N | 2 |
| Hernández Ibáñez, C | 1 |
| de Troya, M | 1 |
| Bergón-Sendín, M | 1 |
| Pulido-Pérez, A | 1 |
| Sáez-Martín, LC | 1 |
| Suárez-Fernández, R | 1 |
| Varella, AY | 1 |
| Cucato, GG | 1 |
| Toledo-Pastrana, T | 1 |
| Nieto-Guindo, M | 1 |
| Pariser, DM | 1 |
| Krishnaraja, J | 1 |
| Tremblay, TM | 1 |
| Rubison, RM | 1 |
| Love, TW | 1 |
| McGraw, BF | 1 |
| Wozniacki, L | 1 |
| Zubilewicz, T | 1 |
| Kim, WO | 1 |
| Kil, HK | 1 |
| Yoon, KB | 1 |
| Yoo, JH | 1 |
| Grootens, KP | 1 |
| Jatene, FB | 1 |
| Revuz, J | 1 |
| Maillard, H | 1 |
| Fenot, M | 1 |
| Bara, C | 1 |
| Célérier, P | 1 |
| Munia, MA | 1 |
| BiscegliJatene, F | 1 |
| Try, C | 1 |
| Messikh, R | 1 |
| Elkhyat, A | 1 |
| Aubin, F | 1 |
| Humbert, RP | 1 |
| Shimizu, H | 1 |
| Tamada, Y | 1 |
| Shimizu, J | 1 |
| Ohshima, Y | 1 |
| Matsumoto, Y | 1 |
| Sugenoya, J | 1 |
| Tupker, RA | 2 |
| Harmsze, AM | 2 |
| Deneer, VH | 2 |
| Mijnhout, GS | 1 |
| Kloosterman, H | 1 |
| Simsek, S | 1 |
| Strack van Schijndel, RJ | 1 |
| Netelenbos, JC | 1 |
| Lefrandt, JD | 1 |
| Maurer, JM | 1 |
| Houte, Mv | 1 |
| Arroyo, HA | 1 |
| Di Blasi, M | 1 |
| Fejerman, N | 1 |
| LeWitt, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis[NCT01956591] | 1,100 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| The Use of Oxybutynin in Women After Thoracoscopic Sympathectomy and the Effect on Plantar Hyperhidrosis[NCT01328015] | Phase 2 | 32 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Prospective Study Assessing the Effect of Patient Characteristics on Treatment Response in Hyperhidrosis[NCT03694093] | 41 participants (Actual) | Observational | 2018-08-20 | Completed | |||
| The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.[NCT02973659] | 61 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for oxybutynin and Hyperhidrosis
| Article | Year |
|---|---|
Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials.
Topics: Humans; Hyperhidrosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature.
Topics: Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Quality of Life; Retrospective Studie | 2021 |
Treatment of Primary Craniofacial Hyperhidrosis: A Systematic Review.
Topics: Botulinum Toxins, Type A; Cholinergic Antagonists; Facial Dermatoses; Ganglionectomy; Glycopyrrolate | 2015 |
Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis.
Topics: Acetylcholine Release Inhibitors; Acne Vulgaris; Algorithms; Alopecia; Anti-Bacterial Agents; Antipe | 2015 |
Oxybutynin: dry days for patients with hyperhidrosis.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Sweat Glands | 2006 |
Oxybutynin: dry days for patients with hyperhidrosis.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Sweat Glands | 2006 |
Oxybutynin: dry days for patients with hyperhidrosis.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Sweat Glands | 2006 |
Oxybutynin: dry days for patients with hyperhidrosis.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Sweat Glands | 2006 |
16 trials available for oxybutynin and Hyperhidrosis
| Article | Year |
|---|---|
A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study.
Topics: Double-Blind Method; Humans; Hyperhidrosis; Mandelic Acids; Sweat; Treatment Outcome | 2023 |
Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial.
Topics: Humans; Hyperhidrosis; Pilot Projects; Quality of Life; Treatment Outcome | 2023 |
Long-term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open-label extension study.
Topics: Adolescent; Double-Blind Method; Humans; Hyperhidrosis; Mandelic Acids; Treatment Outcome | 2023 |
Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
Topics: Administration, Topical; Adolescent; Adult; Double-Blind Method; Female; Gels; Humans; Hyperhidrosis | 2017 |
Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis.
Topics: Adolescent; Adult; Aged; Axilla; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adm | 2014 |
Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy.
Topics: Adult; Female; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Patient Satisfaction; | 2014 |
Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up | 2014 |
Long-term results of oxybutynin treatment for palmar hyperhidrosis.
Topics: Adolescent; Adult; Body Mass Index; Child; Child, Preschool; Female; Hand; Humans; Hyperhidrosis; Ma | 2014 |
Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Humans; Hyperhidrosis; Male; Mandelic A | 2015 |
Initial study of transdermal oxybutynin for treating hyperhidrosis.
Topics: Administration, Cutaneous; Adult; Aged; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2017 |
Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Hyperhidros | 2017 |
An alternative to treat palmar hyperhidrosis: use of oxybutynin.
Topics: Adolescent; Adult; Epidermis; Hand; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Parasympatho | 2011 |
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Hy | 2012 |
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Hy | 2012 |
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Hy | 2012 |
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Hy | 2012 |
Effectiveness of iontophoresis with alternating current (AC) in the treatment of patients with palmoplantar hyperhidrosis.
Topics: Adult; Cholinergic Antagonists; Female; Foot Diseases; Hand; Humans; Hyperhidrosis; Iontophoresis; M | 2003 |
Oxybutynin therapy for generalized hyperhidrosis.
Topics: Administration, Oral; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagon | 2006 |
Oxybutynin therapy for generalized hyperhidrosis.
Topics: Administration, Oral; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagon | 2006 |
Oxybutynin therapy for generalized hyperhidrosis.
Topics: Administration, Oral; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagon | 2006 |
Oxybutynin therapy for generalized hyperhidrosis.
Topics: Administration, Oral; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagon | 2006 |
Exercise-induced sweating in healthy subjects as a model to predict a drug's sweat-reducing properties in hyperhydrosis: a prospective, placebo-controlled, double-blind study.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Drug Evaluation; Exercise; Humans; Hyperhidrosis; Ma | 2008 |
36 other studies available for oxybutynin and Hyperhidrosis
| Article | Year |
|---|---|
Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases.
Topics: Administration, Oral; Adolescent; Adult; Axilla; Drug Administration Schedule; Face; Female; Follow- | 2020 |
Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study.
Topics: Botulinum Toxins, Type A; Humans; Hyperhidrosis; Mandelic Acids; Prospective Studies; Quality of Lif | 2020 |
Tolerance of oral oxybutynin in the treatment of hyperhidrosis.
Topics: Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Retrospective Studies; Treatment Outc | 2020 |
Survival study of treatment adherence by patients given oral glycopyrrolate for hyperhidrosis following treatment failure with oral oxybutynin.
Topics: Adult; Female; Glycopyrrolate; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Prospe | 2020 |
Oxybutynin in primary hyperhidrosis: A long-term real-life study.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Hyperhidrosis; Longitudinal Studies; Male; Mandelic | 2020 |
Craniofacial hyperhidrosis: Clinical characteristics and response to treatment in a cohort of 97 patients treated with oral oxybutynin.
Topics: Axilla; Humans; Hyperhidrosis; Mandelic Acids; Prospective Studies; Treatment Outcome | 2021 |
Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin chloride 10.
Topics: Axilla; Humans; Hyperhidrosis; Mandelic Acids; Quality of Life; Treatment Outcome | 2021 |
Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment.
Topics: Adult; Deprescriptions; Female; Glycopyrrolate; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic An | 2016 |
Videothoracoscopic Sympathectomy Results after Oxybutynin Chloride Treatment Failure.
Topics: Adolescent; Adult; Brazil; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagonis | 2017 |
PURLs: Oral agent offers relief from generalized hyperhidrosis
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic A | 2017 |
Survival study of treatment adherence by patients given oral oxibutynin for hyperhidrosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Child, Preschool; Female; Humans; Hyperhidrosi | 2018 |
Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults.
Topics: Administration, Topical; Adolescent; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Parasympat | 2018 |
Combination of topical agents and oxybutynin as a therapeutic modality for patients with both osmidrosis and hyperhidrosis.
Topics: Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Antifungal Agents; Child; Child, | 2018 |
Adjusting oral oxybutynin medication for hyperhidrosis to reflect seasonal temperature variations.
Topics: Administration, Oral; Adult; Drug Dosage Calculations; Female; Humans; Hyperhidrosis; Male; Mandelic | 2018 |
Use of oxybutynin for treating plantar hyperhidrosis.
Topics: Adolescent; Adult; Aged; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle Aged; Muscarini | 2013 |
Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Mid | 2014 |
Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Hyperhidrosis; Male; Mandelic Acids; Mid | 2014 |
Invited commentary.
Topics: Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Patient Satisfaction | 2014 |
Long-term results of the use of oxybutynin for the treatment of plantar hyperhidrosis.
Topics: Adolescent; Adult; Aged; Algorithms; Child; Female; Foot Dermatoses; Humans; Hyperhidrosis; Mandelic | 2015 |
Treatment of compensatory hyperhidrosis after sympathectomy with botulinum toxin and anticholinergics.
Topics: Adult; Aged; Botulinum Toxins; Cholinergic Antagonists; Female; Humans; Hyperhidrosis; Male; Mandeli | 2015 |
Oral oxybutynin for the treatment of hyperhidrosis: outcomes after one-year follow-up.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Child, Preschool; Female; Follow-Up Studies; H | 2017 |
Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers.
Topics: Administration, Oral; Adolescent; Age Factors; Child; Dose-Response Relationship, Drug; Drug Adminis | 2016 |
Oral glycopyrrolate after the failure of oral oxybutynin in the treatment of primary hyperhidrosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Drug Administration Schedule; Female; Glycopyr | 2017 |
Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis.
Topics: Administration, Cutaneous; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; M | 2016 |
Translation and validation of Hyperhidrosis Disease Severity Scale.
Topics: Adolescent; Adult; Brazil; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle Aged; Quality | 2016 |
Primary hyperhidrosis controlled with oxybutynin after unsuccessful surgical treatment.
Topics: Humans; Hyperhidrosis; Male; Mandelic Acids; Parasympatholytics; Sympathectomy; Young Adult | 2009 |
Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Postmenopause; P | 2010 |
Oxybutynin for antidepressant-induced hyperhidrosis.
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2011 |
[Retrospective studies and therapeutic research].
Topics: Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Parasympatholytics | 2011 |
[Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis].
Topics: Adult; Drug Evaluation; Female; Follow-Up Studies; Humans; Hyperhidrosis; Male; Mandelic Acids; Midd | 2011 |
The use of oxybutynin for treating axillary hyperhidrosis.
Topics: Adolescent; Adult; Axilla; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Hu | 2011 |
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2012 |
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2012 |
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2012 |
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2012 |
Treatment of hyperhidrosis with oxybutynin.
Topics: Adult; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Parasympatholytics; Urinary Bl | 2007 |
Oxybutynin for hyperhidrosis.
Topics: Adolescent; Adult; Depression; Female; Glycopyrrolate; Humans; Hyperhidrosis; Male; Mandelic Acids; | 2007 |
Episodic spontaneous hypothermia with hyperhidrosis.
Topics: Body Temperature Regulation; Cyproheptadine; Female; Humans; Hyperhidrosis; Hypothermia; Infant; Man | 1994 |
Hyperhidrosis and hypothermia responsive to oxybutynin.
Topics: Body Temperature; Humans; Hyperhidrosis; Hypothermia; Mandelic Acids; Urination Disorders | 1988 |